Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
KORU Medical SystemsKRMD -0.28%81 14-Day RSI is 33.26 as of Aug. 08, 2026. GuruFocus rates KRMD with a GF Score™ of 81/100 and a GF Value™ of $4.00 (Modestly Undervalued). Among 866 Medical Devices & Instruments companies, KORU Medical Systems ranks better than 92.26% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
KORU Medical Systems (NAS:KRMD) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
KORU Medical Systems 14-Day RSI Related Terms
KRMD vs PDEX, EMBC, UTMD: 14-Day RSI Comparison
For the Medical Instruments & Supplies subindustry, KORU Medical Systems's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
KORU Medical Systems 14-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, KORU Medical Systems's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where KORU Medical Systems's 14-Day RSI falls into.
KORU Medical Systems (NAS:KRMD) 14-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KORU Medical Systems (KRMD) has a 14-Day RSI of 33.26 as of Aug. 08, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on KORU Medical Systems and its competitors. According to the industry distribution chart, KORU Medical Systems ranks #67 out of 866 companies in the Medical Devices & Instruments industry, placing it in the top 7.7%.
Is KORU Medical Systems' 14-Day RSI too high?
KORU Medical Systems' current 14-Day RSI is 33.26. The Medical Devices & Instruments industry median 14-Day RSI is 49.78. KORU Medical Systems' value of 33.26 is 33.2% below this industry median. Based on the distribution chart, KORU Medical Systems ranks #67 out of 866 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, KORU Medical Systems has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does KORU Medical Systems' 14-Day RSI compare to PDEX and EMBC?
According to the Medical Devices & Instruments industry distribution chart, KORU Medical Systems ranks #67 out of 866 companies for 14-Day RSI. This places KORU Medical Systems in the top 8% of its industry — outperforming the majority of peers. The industry median 14-Day RSI is 49.78. KORU Medical Systems' value of 33.26 is 33.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Devices & Instruments company?
The median 14-Day RSI among Medical Devices & Instruments companies is 49.78, based on 866 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. KORU Medical Systems's current 14-Day RSI of 33.26 is 33.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on KORU Medical Systems and its competitors. For the Medical Devices & Instruments industry, the median 14-Day RSI is 49.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. KORU Medical Systems's current 14-Day RSI is 33.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KORU Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, KORU Medical Systems (KRMD) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.00, compared to a current price of $3.55 — trading 11.3% below its estimated fair value. The current 14-Day RSI is 33.26 and 33.2% below the Medical Devices & Instruments industry median of 49.78. KORU Medical Systems' overall GF Score™ is 81/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For KORU Medical Systems (KRMD), the current 14-Day RSI is 33.26 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is KORU Medical Systems (KRMD) Overvalued in 2026?
Based on GuruFocus' analysis, KORU Medical Systems stock appears to be undervalued.
The current stock price of $3.55 is trading 11.3% below its estimated GF Value™ of $4.00.
GuruFocus considers KORU Medical Systems to be Modestly Undervalued.
Key valuation signals for KRMD:
14-Day RSI: 33.26
GF Value™: $4.00 vs. price of $3.55 (11.3% below fair value)
Industry Position: 33.2% below the Medical Devices & Instruments median (#67 of 866)
No single metric tells the full story. See the KRMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.
81GF Score
Get the complete analysis for KRMD
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KRMD has been successfully added to your 
